Mylan Pharmaceuticals Inc. and Mylan Securitization LLC’s Securitization Facility
March 24, 2015
Cravath represented the initial servicer, Mylan Pharmaceuticals Inc., and seller, Mylan Securitization LLC, a wholly owned special purpose subsidiary of Mylan Pharmaceuticals Inc., in connection with their $400 million accounts receivable securitization facility. The transaction closed on January 27, 2015.
The Cravath team included partner George E. Zobitz and associate C. Daniel Haaren on banking matters; associate Chase A. M. Proctor on structured finance and securitization matters; and partner J. Leonard Teti II and associates Stephen R. Severo and Peter W. Rogers on tax matters. Caitlin M. Hyduke also worked on banking matters and Kiran Sheffrin also worked on tax matters.
Related Practices & Industries
People
-
J.D., 1995, New York University School of Lawwith Honors, cum laude
-
B.A., 1991, Franklin & Marshall College
- New York
Education
Admitted In
- Photo
-
-
J.D., 2005, University of Virginia School of LawOrder of the Coif
-
A.B., 1999, Princeton Universitywith Honors
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
April 29, 2024
Mylan’s Appellate Win Affirming Summary Judgment in Securities Class Action
On Monday, April 15, 2024, the U.S. Court of Appeals for the Second Circuit affirmed the U.S. District Court for the Southern District of New York’s granting of summary judgment in favor of Cravath client Mylan in a securities class action related to Mylan’s marketing, pricing and classification of EpiPen as well as alleged conduct concerning generic drug price fixing and market allocation.
